| 1025CODR Study ID | <u>n</u> | Study Name | Contributor | References |
|-------------------|----------|--|--|------------|
| TB-1003 | 69 | Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (CL-010) | TB Alliance | 1 |
| TB-1005 | 68 | Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (TMC207-CL001) | TB Alliance | 2 |
| TB-1007 | 69 | PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis | TB Alliance | 3 |
| TB-1008 | 85 | Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001) | TB Alliance | 4 |
| TB-1011 | 207 | Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002) | TB Alliance | 5 |
| TB-1014 | 105 | Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z) (NC-003) | TB Alliance | 6 |
| TB-1020 | 827 | An international multicentre controlled clinical trial to evaluate high dose RIFApentine and a QUINolone in the treatment of pulmonary tuberculosis | St. Georges University of London | 7 |
| TB-1021 | 1931 | Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis (REMoxTB) | TB Alliance | 8 |
| TB-1022 | 1690 | A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis (OFLOTUB) | World Health Organization | 9 |
| TB-1024 | 393 | A Prospective Study of Shortening the Duration of Standard Short Course Chemotherapy from 6 Months to 4 Months in HIV-non-infected Patients with Fully Drug-Susceptible, Non-cavitary Pulmonary Tuberculosis with Negative Sputum Cultures after 2 Months of Anti-TB Treatment | Case Western University | 10 |
| TB-1025 | 953 | Controlled Clinical Trial of 4 Short-Course (6-Month) Regimens of Chemotherapy for Treatment of Pulmonary Tuberculosis, East African 2nd Study (T) 1972 | British Medical Research Council | 11 |

| TB-1026 | 1025 | Controlled Clinical Trial of 5 Short-Course (4-Month) Chemotherapy Regimens in Pulmonary Tuberculosis, East African | British Medical Research | 12,13 |
|---------|------|---|-----------------------------|-------|
| | | 4th Study (X) 1976 | Council | |
| TB-1027 | 1133 | Controlled Clinical Trial of 4 Short-Course (6-Month) Regimens of | British Medical | 14-17 |
| | | Chemotherapy for Treatment of Pulmonary Tuberculosis, East | Research | |
| | | African Investigation (R) 1970 | Council | |
| TB-1028 | 1044 | 1 | British Medical | 18,19 |
| | | Treatment of Pulmonary Tuberculosis, Hong Kong 2nd Short | Research | |
| | | Course Investigation 1974 | Council | |
| TB-1029 | 1207 | Third Study of Short-Course Chemotherapy in the Treatment of | British Medical | 20,21 |
| | | Pulmonary Tuberculosis in Hong Kong, 1977 | Research | |
| | | | Council | |
| TB-1030 | 1355 | Two 8-month regimens of chemotherapy for treatment of newly | British Medical | 22 |
| | | diagnosed pulmonary tuberculosis: international multicentre | Research | |
| | | randomised trial | Council | |
| TB-1031 | 72 | Randomized, Open Label, Multiple Dose Phase I Study of the | Case Western | 23 |
| | | Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, | University | |
| | | and Moxifloxacin in HIV-non-infected Adults with Initial Episodes | | |
| | | of Sputum Smear-Positive Pulmonary Tuberculosis | | |

References

- 1. Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (CL-010) Full Text View ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT00944021. (Accessed: 7th December 2018)
- 2. Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (TMC207-CL001) Full Text View ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT01215110. (Accessed: 7th December 2018)
- 3. PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis Full Text View ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT00567840 (Accessed: 7th December 2018)
- 4. Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001) Full Text View ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT01215851 (Accessed: 7th December 2018)

- 5. Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002) Full Text View ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT0149841. (Accessed: 7th December 2018)
- 6. Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z) Full Text View ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT01691534. (Accessed: 7th December 2018)
- 7. Jindani, A. et al. High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis. N. Engl. J. Med. 371, 1599–1608 (2014).
- 8. Gillespie, S. H. et al. Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis. N. Engl. J. Med. 371, 1577–1587 (2014).
- 9. Merle, C. S. et al. A Four-Month Gatifloxacin-Containing Regimen for Treating Tuberculosis. N. Engl. J. Med. 371, 1588–1598 (2014).
- 10. Johnson, J. L. *et al.* Shortening Treatment in Adults with Noncavitary Tuberculosis and 2-Month Culture Conversion. *Am. J. Respir. Crit. Care Med.* **180**, 558–563 (2009).
- 11. CONTROLLED CLINICAL TRIAL OF FOUR SHORT-COURSE (6-MONTH) REGIMENS OF CHEMOTHERAPY FOR TREATMENT OF PULMONARY TUBERCULOSIS: SECOND EAST AFRICAN/BRITISH MEDICAL RESEARCH COUNCIL STUDY. *The Lancet* **304**, 1100–1106 (1974).
- 12. CONTROLLED CLINICAL TRIAL OF FIVE SHORT-COURSE (4-MONTH) CHEMOTHERAPY REGIMENS IN PULMONARY TUBERCULOSIS: First Report of 4th Study EAST AFRICAN AND BRITISH MEDICAL RESEARCH COUNCILS. *The Lancet* **312**, 334–338 (1978).
- 13. Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Second report of the 4th study. East African/British Medical Research Councils Study. *Am. Rev. Respir. Dis.* **123**, 165–170 (1981).
- 14. CONTROLLED CLINICAL TRIAL OF SHORT-COURSE (6-MONTH) REGIMENS OF CHEMOTHERAPY FOR TREATMENT OF PULMONARY TUBERCULOSIS. *The Lancet* **299**, 1079–1085 (1972).
- 15. Councils, E. A. M. R. CONTROLLED CLINICAL TRIAL OF FOUR SHORT-COURSE (6-MONTH) REGIMENS OF CHEMOTHERAPY FOR TREATMENT OF PULMONARY TUBERCULOSIS. *The Lancet* **301**, 1331–1339 (1973).
- 16. Councils, E. A. M. R. CONTROLLED CLINICAL TRIAL OF FOUR SHORT-COURSE (6-MONTH) REGIMENS OF CHEMOTHERAPY FOR TREATMENT OF PULMONARY TUBERCULOSIS. *The Lancet* **304**, 237–240 (1974).
- 17. Results at 5 years of a controlled comparison of a 6-month and a standard 18-month regimen of chemotherapy for pulmonary tuberculosis. *Am. Rev. Respir. Dis.* **116**, 3–8 (1977).

- 18. Hong Kong Chest Service/British Med. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis: The results up to 24 months. *Tubercle* **60**, 201–210 (1979).
- 19. Controlled Trial of 6-Month and 8-Month Regimens in the Treatment of Pulmonary Tuberculosis. Am. Rev. Respir. Dis. 118, 219–227 (1978).
- 20. Council, H. K. C. S. M. R. CONTROLLED TRIAL OF FOUR THRICE-WEEKLY REGIMENS AND A DAILY REGIMEN ALL GIVEN FOR 6 MONTHS FOR PULMONARY TUBERCULOSIS. *The Lancet* **317**, 171–174 (1981).
- 21. Five-Year Follow-Up of a Controlled Trial of Five 6-Month Regimens of Chemotherapy for Pulmonary Tuberculosis. *Am. Rev. Respir. Dis.* **136**, 1339–1342 (1987).
- 22. Jindani, A., Nunn, A. & Enarson, D. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. *The Lancet* **364**, 1244–1251 (2004).
- 23. Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis Full Text View ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT00396084. (Accessed: 7th December 2018)